---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-023689"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:54:31.566141+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q2 net loss $5.4M; cash $3.1M; BARDA contract terminated; GEO-MVA gets EU guidance

## Summary
- Net loss $5.37M ($0.35/share) vs $5.06M ($1.99/share) in Q2 2024; per-share loss down on share dilution.
- Revenue from BARDA/RRPV contract $852k; BARDA terminated contract for convenience in Q2.
- Cash $3.09M at June 30; completed July 2025 public offering netting ~$5.6M.
- GEO-MVA received favorable EMA guidance allowing single Phase 3 immuno-bridging trial; trial expected 2H 2026.
- GEO-CM04S1 showed superior T-cell responses vs mRNA in CLL; mRNA arm failed endpoint, enrollment restricted to GEO-CM04S1.

## SEC filing metadata
- accession: 0001437749-25-023689
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/0001437749-25-023689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/govx20250725_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-023689
- JSON: https://secwatch.observer/filing/0001437749-25-023689.json
- Plain text: https://secwatch.observer/filing/0001437749-25-023689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.